🍂 Enjoy the Fall Season! 🍂
MindTheDesk

IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors

General Montana • November 15, 2026 •
IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors
Development candidate demonstrates encouraging preclinical activity in CDKN2A-deficienct tumor models as a monotherapy and in combination with inhibitors of RAS and MTAP, including IDEAYA's proprietary Phase 1 PRMT5 inhibitor IDE892CDKN2A-deficiency is a common tumor suppressor loss prevalent in ~10-15% of…
Source: Missoulian MT | https://missoulian.com/search/?f=rss&t=article&l=50&s=start_time&sd=desc - Read Original
"Free Quote Today"

Discussion (0)

Please log in to post a comment.

No comments yet. Be the first to share your thoughts!

Sponsored
"Get your business promoted today."